A5070493419- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Inflammatory mediators and NSAID effects
- Glycosylation and Glycoproteins Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Cytokine Signaling Pathways and Interactions
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Nutrition, Genetics, and Disease
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Myasthenia Gravis and Thymoma
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Genetics, Bioinformatics, and Biomedical Research
- Lung Cancer Research Studies
- Chromatography in Natural Products
- Cell Adhesion Molecules Research
- Caveolin-1 and cellular processes
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- Neuroblastoma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
Tokyo National Hospital
2015-2025
National Cancer Center Hospital East
2017-2025
National Center for Global Health and Medicine
2014-2023
National Cancer Center
2022
AntiCancer (United States)
2019-2020
University of California, San Diego
2019-2020
The University of Tokyo
2019
National Cancer Centre Japan
2015
National Disaster Medical Center
2014
National Hospital Organization
2014
IntroductionThymic carcinoma (TC) is a rare cancer with poor prognosis and limited treatment options, especially after relapse.MethodsIn this open-label, two-stage, multicentre, single-arm phase II trial, the main eligibility criteria were unresectable or recurrent TC, an Eastern Cooperative Oncology Group–performance status of 0 1, progression at least one chemo(radio)therapy no history autoimmune disease. Nivolumab was administered dose 3 mg/kg every 2 weeks. The primary end-point response...
Highlights•PD-L1 was positive in 67% of thymoma (TM) and 41% thymic carcinoma (TC).•Changes PD-L1 expression were evaluated TM/TCs by the antibody (E1L3N).•Chemotherapy induced PD-1 TMs.•Immune check point therapies warranted TM/TCs.AbstractBackgroundsTo understand clinical impact PD-1/L1 (TC), we frequency pre/post chemotherapy specimens correlation with treatment efficacy.MethodsThe using immunohistochemistry patients TM or TC treated between 2000 2014. Using formalin-fixed,...
Background/Aim: Liver metastasis in colorectal-cancer is a recalcitrant disease. To develop precision individualized therapy of this disease, we developed patient-derived orthotopic xenograft (PDOX) model liver metastasis. In the present report, evaluated efficacy oral recombinant methioninase (o-rMETase) combination with 5-fluorouracil (5-FU) and oxaliplatinum (OXA) on PDOX mouse model. Materials Methods: Colorectal-cancer models were randomized into three groups seven mice. Group 1,...
Genotype-matched trials, which are becoming increasingly important in the precision oncology era, require referrals from institutions providing comprehensive genomic profiling (CGP) testing to those conducting these and travel burden for trial participation is significant. However, it remains unknown whether time or distance associated with genotype-matched participation.To assess disparities following CGP testing.This retrospective cohort study June 2020 2022 included patients advanced...
Cancer remains a formidable global health challenge affecting millions of lives annually. For decades, conventional cancer treatments used one-size-fits-all approach, overlooking the intricate genetic variations that drive tumors. The emergence genomics has ushered in new era
2543 Background: Glypican 3 (GPC3) is a member of the glypican family heparan sulfate proteoglycans that are attached to cell surface by glycosylphosphatidylinositol anchor. High GPC3 expression rates reported in numerous cancer types with high unmet medical need, including hepatocellular carcinoma (HCC). TAK-102 GPC3-targeted autologous chimeric antigen receptor T (CAR-T) immunotherapy armored IL-7 and CCL19. The addition CCL19 construct was designed support expansion memory subsets...
ABSTRACT CBA‐1205 is a novel humanized antibody targeting delta‐like 1 homolog (DLK1) that enhances antibody‐dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma and neuroblastoma. demonstrates potent antitumor activity multiple tumor models, making it potential treatment option for DLK1‐expressing cancers. This first‐in‐human, open‐label Phase I study includes three parts. Part 1, the dose‐escalation phase,...
<p>Figure S1 shows the study design.</p>
<p>Figure S2 shows the study progression and dose steps.</p>
8626 Background: The clinico-genomic factors influencing clinical trial participation and their impact on outcomes remain unclear. We investigated which characteristics predict in patients with metastatic NSCLC whether improves compared to nonparticipation, using a nationwide database. Methods: retrospectively analyzed 2,966 who underwent comprehensive genomic profiling (CGP) testing from March 2019 December 2023 the Center for Cancer Genomics Advanced Therapeutics, Multivariable logistic...
Abstract Background Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines. Methods This prospective study assessed seroconversion rate COVID-19 vaccines among patients cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before first vaccination, 1–3 4–6 months after second vaccination. The...